the core secondary stem-loop structure (nucleotides ϩ18 to ϩ44) is critical for Tat-TAR interactions and for Tat-mediated transactivation. The bulge region in TAR (ϩ22 to ϩ24) serves as the primary binding site for Tat, and the loop sequences (ϩ30 to ϩ35) also contribute to this interaction (65, 66, 72) . TAR RNA essentially serves as an anchor for Tat and certain cellular factors (TRP-185 and p68) (52, 73) to facilitate interactions with promoter elements such as TATA, Sp1, and the HIV-1 enhancer (11, 43) . Deletion of NF-B-and Sp1-binding sites from the HIV-1 promoter abrogates Tat-mediated transactivation, suggesting that once brought into the vicinity of the promoter, Tat interacts with transcription factors bound at the NF-B/Sp1 region to stimulate transcription initiation and stabilize elongation complexes (10) . Tat may be able to transactivate independently of TAR RNA, since TAR-defective viruses are replication competent but still require Tat. In each case, the Tat-responsive element maps to the NF-B sites within the HIV-1 enhancer (1, 5, 76) .
The NF-B/Rel family of transcription factors plays a pivotal role in the regulation of the immunomodulatory genes and activates genes including cytokines, cell surface receptors, and acute-phase proteins, as well as viral genes including the HIV-1 LTR (for reviews, see references 4, 64, and 79). The NF-B/ Rel family members can be subdivided into two subgroups based on their structure and function: (i) the DNA-binding proteins NF-B1 (p50) (16, 33, 44) , NF-B2 (p52) (15, 57, 71) , RelA (p65) (58, 67) , c-Rel (20) , and RelB (68, 69) , and (ii) the NF-B1 (p105) and NF-B (p100) precursors, which are pro-teolytically cleaved to generate DNA-binding proteins (p50 and p52, respectively) (15, 16, 33, 44, 57, 71) . All members of the family share an N-terminal 300-amino-acid homology region involved in the formation of a DNA-binding dimer complex which associates with a decameric consensus sequence, 5Ј-GGGPuNNPyPyCC-3Ј, found in the promoters of several target genes (reviewed in references 4, 64, and 79). The dimer composition of NF-B contributes to the differential specificity of gene activation (48, 60) .
NF-B activity is regulated in part at the level of subcellular localization. In unstimulated cells, the NF-B complex is retained in the cytoplasm by inhibitory IB proteins which bind to and mask the nuclear localization sequence contained within the Rel homology domain, thus preventing the translocation of the DNA-binding proteins (8, 9) . All the members of IB family, including IB␣ (36) , IB␤ (77) , IB␥ (32, 41) , and Bcl-3 (37, 56) , as well as the precursor proteins p105 (50) and p100 (54) , contain multiple ankyrin repeats. These sequences represent the minimal requirements for IB function as they are involved in the physical interaction with NF-B DNAbinding subunits and in inhibitory activity (40, 42) . The most extensively studied of the IB proteins is IB␣. Upon stimulation by many activating agents, including cytokines, viruses, and double-stranded RNA, IB␣ is rapidly phosphorylated and degraded, resulting in the release of NF-B (8). Phosphorylation of IB␣ does not impair the ability of IB␣ to associate with NF-B but, rather, represents a signal for degradation of the inhibitor (2, 26, 49, 78) via the ubiquitin-proteasome degradation pathway (21) . Once released, NF-B is able to activate target genes until new IB␣ is synthesized. Since IB␣ contains NF-B-binding sites in its promoter, NF-B is able to autoregulate the transcription of its own inhibitor (19, 22, 46, 75) . This autoregulatory control of IB␣/NF-B expression is in part responsible for the transient nature of the NF-B activation of gene expression.
Recent studies demonstrated that mutation of either Ser-32 or Ser-36 blocked signal-induced IB␣ phosphorylation and degradation (17, 18, 21) . Constitutive phosphorylation of IB␣ in the C-terminal PEST (proline, glutamate, serine, threonine) domain by casein kinase II has also been demonstrated, and triple point mutation of IB␣ at Ser-283, Thr-291, and Thr-299 eliminated constitutive phosphorylation in vitro and in vivo (6, 47) . Together with results demonstrating a role for S32/S36 sites in inducer-mediated phosphorylation and degradation of IB␣, these studies define the regulatory phosphorylation sites in IB␣.
In this study, we demonstrate that Tat synergizes with TNF-␣ via NF-B induction to transactivate the HIV-1 LTRdriven gene expression. We also show that IB␣ is able to inhibit the Tat-TNF-␣ synergistic activation of the HIV-1 LTR in a dose-dependent manner. IB␣ molecules mutated in Nterminal sites involved in inducer-mediated phosphorylation were stable in transfected cells (t 1/2 , Ͼ4 h) and efficiently blocked HIV-1 LTR-directed gene expression and reduced HIV-1 multiplication in a single-cycle infection model. These experiments suggest a strategy that may contribute to the inhibition of HIV-1 gene expression by interfering with the NF-B/Rel signaling pathway.
MATERIALS AND METHODS
Plasmid and cell lines. Plasmids SVK3-IB␣ and SVK3-IB␣(3C) encoding wild-type IB␣ and IB␣(3C), respectively, are described elsewhere (39, 47) . IB␣(3C) is a full-length human IB␣ in which serine 283, threonine 291, and threonine 299 are substituted by alanine residues. The substitutions S32A and S36A in mutant IB␣(2N) and S32A, S36A, S283A, T291A, and T299A in mutant IB␣(2Nϩ3C) were generated by overlap PCR mutagenesis with Pfu DNA polymerase. The resulting mutated IB␣ cDNAs were inserted in expression vector SVK3 (Pharmacia) and plasmid pREP-9 CMVt (7). The presence of the mutations was confirmed by sequencing. HIV-1 LTR chloramphenicol acetyltransferase (CAT) plasmids ptzIIICAT, Ϫ109/Ϫ79, III⌬23, and III⌬A were a kind gift from Eric Cohen (for a schematic map, see Fig. 2 ). The plasmids expressing wild-type and R52Q, R53Q mutant Tat, HIV-1 LTR (⌬B and ⌬B-ACU, respectively), as well as the plasmid containing the HIV-1 proviral DNA (pSVC21 BH10), were described previously (23, 25, 65) . Cell lines inducibly expressing wild-type IB␣ or IB␣(3C), tTA-IB␣(wt), and tTA-IB␣(3C), respectively, are described elsewhere (7) . tTA 3T3 cells were transfected with pREP9-CMV t -IB␣(2N) or pREP9-CMV t -IB␣(2Nϩ3C). Cells which inducibly expressed IB␣(2N) or IB␣(2Nϩ3C) were selected and maintained in Dulbecco's modified Eagle's medium containing 10% calf serum, 300 g of hygromycin B per ml, and 400 g of G418 (Gibco BRL) per ml.
Analysis of HIV-1 LTR transcription in reporter gene experiments. The cells were transiently transfected by the DEAE-dextran method (45) 7 cells in exponential phase were washed once in TS solution, resuspended with the DNA solution, and incubated at room temperature for 20 min. The cells were then incubated at 37ЊC for 30 min in 10 ml with medium containing 10% serum and 0.1 mM chloroquine (Sigma Chemical Co.), after which they were centrifuged and resuspended in fresh medium containing serum. At 32 h after transfection, the cells were induced with 5 ng of ml TNF-␣ (Boehringer Mannheim) per ml. At 16 h after induction, they were harvested and lysed. Extracts (10 to 100 mg) were assayed for CAT activity for 10 to 120 min, depending on the experiment. The percent acetylation was determined by ascending thin-layer chromatography as previously described (31) and quantified with a Bio-Rad Gelscan Phosphoimager and the Molecular Analyst (Bio-Rad) software program.
Immunoblot analysis of IB␣ turnover. tTA-IB␣-expressing cells (7) were cultured in tetracycline-free Dulbecco's modified Eagle's medium supplemented with 10% calf serum and treated with 5 ng of TNF-␣ (Gibco-BRL) per ml and 50 g of cycloheximide per ml for 4 h. The cells were washed with phosphatebuffered saline and lysed in 10 mM Tris HCl (pH 8.0)-60 mM KCl-1 mM EDTA-1 mM dithiothreitol-0.5% Nonidet P-40-0.5 mM phenylmethylsulfonyl fluoride-0.01 g of leupeptin per l-0.01 g of pepstatin per l-0.01 g of aprotinin per l (WBL buffer). Equivalent amounts of protein (20 g) were electrophoresed on a sodium dodecyl sulfate-10% polyacrylamide gel. The proteins were transferred to a nitrocellulose membrane, and IB␣ was detected with IB␣ monoclonal antibody MAD 10B (42) as previously described (59) .
Analysis of HIV-1 protein and RNA synthesis in a single-cycle infection model. Cos-1 cells were transfected with 10 g of HIV-1 proviral DNA (pSVC21 BH10) and 1, 5, or 10 g of IB␣-expressing plasmid: either SVK3-IB␣-IB␣(2N), -IB␣(3C), or -IB␣(2Nϩ3C). In all experiments, the total amount of DNA transfected was completed to 20 g with unrelated DNA (pUC8). DNA was introduced into cells by lipofection (Lipofectamine) as specified by the manufacturer (Promega Inc.). At 3 days after transfection, the medium and the cells were collected. The relative amount of virion protein p24 present in the medium was determined by enzyme-linked immunosorbent assay (ELISA) (61) . Proteins were extracted from a portion of the collected cells by being resuspended in WLB buffer. The proteins were analyzed by immunoblotting as described above with IB␣ monoclonal antibody (42), human serum from an HIV-1-seropositive individual, or actin monoclonal antibody (ICN). Total RNA was extracted from the remaining cells with an RNeasy kit (Qiagen) as specified by the manufacturer. RNA was denatured, electrophoresed through a 1.2% agarose gel in formaldehyde buffer, and transferred to a nylon membrane. Hybridization was carried out with 32 P-labeled, random-primed HIV-1 proviral DNA or ␤-actin cDNA probes. The HIV-1 proviral cDNA probes were the 2-and 2.2-kbp HindIII fragments derived from pSVC21 BH10. The ␤-actin cDNAs used as the probes were the 1-kbp PstI fragments derived from plasmid p␤-actin.
RESULTS

Tat-TNF-␣ stimulation of the HIV-1 LTR.
To determine the specific conditions required for Tat-TNF-␣ synergistic activation of HIV-1 LTR-driven reporter constructs in Jurkat T cells, titration of wtTat expression plasmid and/or recombinant TNF-␣ was initially performed (data not shown). In subsequent experiments, Tat plasmid was used at 2 g while TNF-␣ was used at 5 ng/ml. Tat stimulated the HIV-1 LTR CAT reporter plasmid approximately 10-fold, while TNF-␣ treatment alone induced reporter gene expression about 5-fold (Fig. 1A) . Addition of both activators produced a true synergistic stimulation of the HIV-1 LTR, resulting in a 50-to 70-fold induction of gene expression (Fig. 1A) .
Tat-TNF-␣ synergism requires Tat binding to the TAR element.
Previous studies demonstrated that efficient transactivation of HIV-1 gene expression by Tat required physical interaction between Tat and the TAR element (25) . The R52Q, R53Q point mutations of the HIV-1 Tat protein abrogated Tat binding to the TAR element and gene transactivation (25) . To test whether the Tat-TNF-␣ synergism defined in the above model system required Tat-TAR association, the R52Q, R53Q mutant of Tat (designated TatRQ) was used together with TNF-␣ to stimulate expression of the HIV-1 LTR-driven CAT reporter (Fig. 1B) . Whereas Tat plus TNF-␣ activated the HIV-1 LTR up to 70-fold, TNF-␣ alone, wt Tat alone, or TatRQ alone induced LTR-mediated gene expression 4-, 6-, and 3-fold, respectively. Significantly, the combination of TNF-␣ treatment and TatRQ coexpression was only weakly effective (fivefold induction) in mediating the activation of the HIV-1 LTR (Fig. 1B) . Similarly, mutations within the TAR element (⌬B and B-ACU) that altered the Tat protein-binding site (25, 65) also were not activated by Tat-TNF-␣ treatment ( Fig. 1C and D) . These results thus reflect a requirement for Tat-TAR interactions in the synergistic transactivation of the HIV-1 LTR.
Tat-TNF-␣ synergism requires intact NF-B sites. To characterize the region of the HIV-1 LTR involved in synergistic activation, HIV-1 LTR deletion mutants were transfected into Jurkat cells and stimulated with Tat, TNF-␣, or Tat plus TNF-␣. As expected, the intact LTR-CAT construct (plasmid ptzIIICAT) was strongly inducible by both activators (Fig. 2) , with an 18-fold induction by Tat-TNF-␣. In contrast, the Ϫ109/Ϫ79 plasmid, a construct lacking the NF-B sites, had only baseline level of activity and was not transactivated by TNF-␣. Surprisingly, this construct was not inducible by wtTat expression plasmid, even though it contained an intact TAR element. Nevertheless, the combination of Tat and TNF-␣ was able to stimulate the Ϫ109/Ϫ79 plasmid about fivefold. The III⌬23 construct, which was deleted for the upstream modulatory sequences of the HIV-1 LTR (upstream of Ϫ167), was stimulated by both activators as efficiently as was the wt LTR-CAT plasmid, indicating that the upstream elements in the Ϫ423 to Ϫ167 domain of the LTR did not play a complementary role in Tat-TNF-␣ activation. Plasmid III⌬A was deleted for all of the LTR sequences upstream of Ϫ57 and was not activated significantly by either inducer alone, although a residual fourfold induction was observed with Tat-TNF-␣. This experiment indicates that strong synergistic activation of the HIV-1 LTR by the combination of Tat and TNF-␣ required intact NF-B sites. The fact that some activation could occur in the absence of the enhancer element (in constructs Ϫ109/79 and IIIA) suggests that TNF-␣ may be able to potentiate Tat activity at the TAR element independently of the NF-B sites.
Stability of the IB␣ mutants. Recent experiments have defined specific sites of inducer-mediated and constitutive phosphorylation in the IB␣ regulatory protein (summarized in Fig. 3 ). In particular, mutation of the N-terminal phosphorylation sites at Ser-32 and Ser-36 in the signal response domain of IB␣ prevented inducer-mediated phosphorylation and subsequent proteasome-dependent degradation of IB␣ (17, 18, 21) . Also, triple-point mutation of IB␣ in the C-terminal residues S-283, T-291, and T-299 abrogated constitutive phosphorylation in vivo by casein kinase II and increased the intrinsic stability of IB␣ but did not affect inducer-mediated degradation of IB␣ (47) . IB␣ expression plasmids that produced IB␣ proteins singly mutated in Ser-32 or Ser-36, in , and in all five regulatory phosphorylation sites [IB␣(2Nϩ3C)] were generated. The inducer-mediated turnover of these proteins was analyzed in stably transfected NIH 3T3 cells (7, 47) at different times after treatment with cycloheximide and TNF-␣ (Fig. 4A ). Immunoblot analysis with an IB␣-specific antibody was able to distinguish between the endogenous murine IB␣ and the exogenously expressed human IB␣ (Fig. 4A, lane 1) . Cycloheximide was added to eliminate the complicating effects of de novo synthesis of IB␣ after induction. The endogenous murine IB␣, human wtIB␣, and IB␣(3C) all degraded rapidly in response to TNF-␣ addition, with a t 1/2 of much less than 15 min (lanes 2   FIG. 2 . Maximum Tat-TNF-␣ synergism requires intact NF-B sites. Jurkat T cells were cotransfected with 5 g of ptzIIICAT, Ϫ109/Ϫ79, III⌬23, or III⌬A in the absence or presence of pSVexTat (2 g). TNF-␣ was added at 32 h after transfection, and the mixture was incubated for an additional 16 h. Whole-cell extracts were prepared, normalized for total protein, and assayed for CAT activity (50 g for 30 min). 
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to 6), indicating that triple mutation of S-283, T-291, and T-299 did not affect inducer-mediated degradation of IB␣. In contrast, both S36A (Fig. 4A ) and S32A mutations (data not shown) stabilized IB␣; both point mutations increased the t 1/2 of IB␣ to approximately 90 to 120 min (lanes 2 to 6). Doublepoint mutated IB␣(2N) and IB␣(2Nϩ3C) were extremely stable in the presence of TNF and cycloheximide, with a t 1/2 of greater than 4 h (Fig. 4B ). This experiment demonstrates the increased stability of point-mutated IB␣ molecules and suggests that both IB␣(2N) and IB␣(2Nϩ3C) should be stable transdominant mutants of the NF-B response.
Inhibition of Tat-TNF-␣ activation of the HIV-1 LTR by IB␣ transdominant mutants.
To examine the effect of wt and mutated forms of IB␣ on Tat-TNF-␣ synergistic activation of HIV-1 LTR-directed gene expression, the different forms of IB␣ were cotransfected into Jurkat cells together with the reporter construct and the wtTat expression plasmid. Expression of both wtIB␣ and IB␣(3C) reduced Tat-TNF-␣ activation in a dose-dependent manner from a level of about 70-fold transactivation to 15-to 30-fold induction (Fig. 5) . However, neither wtIB␣ nor IB␣(3C) completely inhibited HIV-1 LTR-mediated expression. Expression of the S32A mutant of IB␣ (or S36A) dramatically reduced Tat-TNF-␣ activation to 10-to 20-fold stimulation. Strikingly, the IB␣(2N) and IB␣(2Nϩ3C) mutants were able to eliminate Tat-TNF-␣ transactivation at low concentrations of inhibitory plasmid; IB␣(2N) or IB␣(2Nϩ3C) at 1 g/ml reduced LTR-directed reporter gene expression to only fivefold stimulation. At higher concentrations, Tat-TNF-␣ transactivation of HIV-1 LTRdriven gene expression was completely suppressed by the transdominant IB␣ mutants (Fig. 5) . 2) . By using a human antiserum that recognizes HIV-1 structural proteins, a dramatic reduction in the amounts of virus-specific p24 core antigen, p55 precursor for virion core proteins, and gp120 envelope glycoprotein was observed in cells expressing IB␣(2N) (Fig. 6A, lanes 6 to 8) . In other experiments with the singlecycle infection model, we found that wtIB␣, IB␣(3C), and IB␣(2Nϩ3C) were also effective in blocking a round of HIV-1 replication but that IB␣(2N) was consistently more effective in a dose-dependent manner. Analysis of the intracellular accumulation of viral mRNA also confirmed that IB␣ and the transdominant negative forms of IB␣ differentially inhibited HIV-1 multiplication (Fig. 7) . Expression of IB␣ inhibited HIV-1 proviral transcription in a dose-dependent manner (Fig. 7A, lanes 3 to 14) . In particular, IB␣(2N) was the strongest inhibitor of HIV-1 transcript accumulation (lanes 6 to 8). Complementary results were obtained when the level of p24 antigen release into the supernatant was measured by an ELISA-based viral antigen capture assay (Fig. 7D) . Together, these results indicate that IB␣(2N) inhibited HIV-1 transcript levels, intracellular viral protein accumulation, and release of virions into the supernatant. Surprisingly, additional mutations within the C-terminal phosphorylation sites in IB␣ (2Nϩ3C) reduced the inhibitory capacity relative to IB␣(2N) (Fig. 6A, lanes 12 to 14; Fig. 7A, lanes 12 to 14) , suggesting an important role for the intact C-terminal PEST domain in the inhibition of HIV-1 multiplication.
DISCUSSION
In the present study, we examined the ability of different forms of IB␣, mutated in distinct regulatory phosphorylation sites, to inhibit the Tat-TNF-␣ synergistic activation of the HIV-1 LTR in Jurkat cells. We found in our Jurkat cell model that transactivation of the HIV-1 LTR was dependent upon both functional Tat-TAR interaction and the presence of NF-B-binding sites in the Ϫ100 enhancer region of the HIV-1 LTR. Coexpression of wtIB␣ or mutant IB␣ inhibited Tat-TNF synergism in a dose-dependent manner. Interestingly, the transdominant mutants IB␣(2N) and IB␣(2Nϩ3C) were each at least five times as effective as wtIB␣ in inhibiting HIV-1 LTR-directed gene expression. Moreover, IB␣(2N) but, surprisingly, not IB␣(2Nϩ3C) was more effective in blocking HIV-1 protein and RNA synthesis in a single-cycle infection model than was wtIB␣ or IB␣(3C). The observation that mutations in the C-terminal PEST domain of IB␣ decreased the inhibitory potential of IB␣(2N) is surprising and indicates that an intact C terminus is required for maximal inhibition of HIV-1 multiplication by IB␣(2N). This effect of the C-terminal domain was not apparent in assays measuring (80) . Tat suppressed the expression of Mn-dependent superoxide dismutase which normally functions as part of the cellular response to oxidative stress, thus shifting the cellular redox state toward prooxidative conditions. Under these conditions, higher levels of NF-Bbinding activity contributing to stimulation of HIV-1 LTRdirected gene expression were observed (23a). Under conditions of maximal Tat-TNF-␣ synergism, IB␣ was nonetheless able to interfere with NF-B induction, by sequestering NF-B in the cytoplasm in a concentration-dependent manner (6a). IB␣ molecules mutated in the N-terminal signal response phosphorylation sites S-32 and/or S-36 did not undergo rapid inducer-mediated degradation (Fig. 4 ) and were at least five times as effective as the wt in blocking LTR-directed gene expression. Our experiments furthermore extend a recent study, published during the review of this paper, demonstrating that IB molecules inhibited Tat-mediated transactivation of the HIV-1 LTR (34).
Biswas et al. showed that Tat protein provided a low level of activation of the viral LTR, even in the absence of a functional TAR element (12, 13) , thus confirming the previously described TAR-independent mode of Tat action (1, 5, 76) . The TAR-independent mode of Tat action was proposed to occur through the transcriptional activation of TNF-␣, which would in turn stimulate NF-B-binding activity (13, 80) . These observations are reminiscent of a study demonstrating that interleukin-2 (IL-2) secretion was upregulated at the transcriptional level by the addition of extracellular Tat to activated T cells. The response element in the IL-2 promoter also mapped to the NF-B site at positions Ϫ206 to Ϫ195 (81). As was observed in the present study, Biswas et al. found that mutations in the NF-B motifs decreased Tat activation dramatically, indicating that maximal stimulation of the LTR-directed gene expression required Tat-TNF-␣ cooperation (13) .
A systematic comparison of HIV-1 LTR activity in human CD4 primary T cells and a transformed lymphoblastoid cell line, J-Jhan, was performed, and strikingly different requirements for maximal LTR activation were observed (1). In unstimulated CD4 T lymphocytes, a low basal level of LTR activity was detected, whereas in the lymphoblastoid cell line, a high spontaneous level of LTR activity that was essentially independent of the NF-B-responsive elements was found. In contrast, in primary lymphocytes, there was an absolute dependence upon the NF-B sites for initiation and Tat-mediated amplification of HIV-1 transcription. These results are in keeping with differences in the permissiveness to HIV-1 replication of primary and established cell types. In lymphoblastoid cell lines, HIV infection resulted in active replication in the absence of other stimuli, whereas in primary T cells, replication was undetectable and was dependent upon T-cell activation for triggering of viral replication (1) . In the present study, we also found that HIV-1 LTR-directed gene activity required both Tat-TAR transactivation and NF-B induction, indicating that our Jurkat cell model may reflect more closely the quiescent state of primary T cells rather than the activated state of other lymphoblastoid cell lines.
Phosphorylation, ubiquitination, and degradation of IB␣ represent critical biochemical events required for NF-B activation (reviewed in references 64 and 79). Recent studies demonstrate that the amino terminus of IB␣ represents a signal response domain for activation of NF-B. Substitution of alanine for either Ser-32 or Ser-36 completely abolished the signal-induced phosphorylation and degradation of IB␣ and blocked the activation of NF-B (17, 18) . These mutations also blocked in vitro ubiquitination of the IB␣ protein (21, 70) . Mutation of C-terminal casein kinase II phosphorylation sites completely blocked constitutive phosphorylation of IB␣ in vivo (6, 47, 53) . The amino terminus of IB␣ is necessary for signal-induced degradation, but inducible degradation of IB␣ also requires the C-terminal domain of the protein (7, 17, 18, 27, 42) . In this regard, the C-terminal domain may contact the N-terminal region of the protein in vivo and act as a hinge or lever to mask the signal response domain (7, 42) .
All of the above studies suggest a transcriptional role for IB␣ in the inhibition of HIV-1 LTR-driven gene expression, consistent with the sequestration of NF-B subunits in the cytoplasm. A recent study by Wu et al., however, implicated IB␣ at a distinct level in the HIV-1 life cycle (82) . By using wtIB␣, HIV-1 replication was blocked at the posttranscriptional level of Rev function, not at a transcriptional level. Because IB␣ did not interact directly with Rev and NF-B expression vectors potentiated Rev stimulation, it was concluded that NF-B/IB regulated a cellular factor required for Rev function (82) . Recent experiments have demonstrated that Rev contains an RNA-binding domain, required for interaction with HIV-1 RNA, and an effector domain, required for RNA-bound Rev to function. The Rev effector domain interacted specifically with host proteins with homology to nucleoporins, a class of proteins that mediate nucleocytoplasmic transport (14, 29, 74) . It is possible that a novel function of IB␣ is to interfere with Rev-mediated nuclear export of viral structural mRNA.
HIV-1 infection causes constitutive activation of NF-B DNA-binding activity in infected cells (64) . A direct temporal correlation exists between HIV-1 infection and the appearance of NF-B DNA-binding activity in myeloid cells (62, 63) , which may in turn prime or stimulate cytokine release. Cytokine release from HIV-1-infected cells may contribute to the elevated levels of TNF-␣, IL-1, IL-6, transforming growth factor ␤, and gamma interferon, present in the sera of AIDS patients in late-stage disease (reviewed in reference 64). Elevated alpha/beta interferon activity is also present in the sera of AIDS patients in late-stage disease and serves as a marker for a poor prognosis (64) . Expression of an IB␣ transdominant mutant may thus interfere with HIV-1 infection at multiple levels: at the level of NF-B dependent transcription activation of the LTR; at the level of Rev posttranscriptional activity; and at the level of expression of HIV-1-induced inflammatory cytokines.
